|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Panarese I, Aquino G, Ronchi A, Longo F,
Montella M, Cozzolino I, Roccuzzo G, Colella G, Caraglia M and
Franco R: Oral and Oropharyngeal squamous cell carcinoma:
Prognostic and predictive parameters in the etiopathogenetic route.
Expert Rev Anticancer Ther. 19:105–119. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen EEW, Bell RB, Bifulco CB, Burtness
B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL,
et al: The Society for immunotherapy of Cancer consensus statement
on immunotherapy for the treatment of squamous cell carcinoma of
the head and neck (HNSCC). J Immunother Cancer. 7:1842019.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Everts HB and Akuailou EN: Retinoids in
cutaneous squamous cell carcinoma. Nutrients. 13:1532021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jia T, Wang F, Qiao B, Ren Y, Xing L,
Zhang H and Li H: Knockdown of LncRNA PANDAR by CRISPR-dCas9
decreases proliferation and increases apoptosis in oral squamous
cell carcinoma. Front Mol Biosci. 8:6537872021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu Y, Zheng Z, Yuan Y, Pathak JL, Yang X,
Wang L, Ye Z, Cho WC, Zeng M and Wu L: The emerging role of
exosomes in oral squamous cell carcinoma. Front Cell Dev Biol.
9:6281032021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Glastonbury CM: Head and Neck Squamous
Cell Cancer: Approach to Staging and Surveillance. In: Diseases of
the Brain, Head and Neck, Spine 2020–2023: Diagnostic Imaging.
Hodler J. (Kubik-Huch RA and von Schulthess GK (eds). Springer,
Cham, CH). 2020. View Article : Google Scholar
|
|
8
|
Cai L, Zhang X, Hou M and Gao F: Natural
flavone tricetin suppresses oxidized LDL-induced endothelial
inflammation mediated by Egr-1. Int Immunopharmacol. 80:1062242020.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Q, Zhao X, Zhang C, Wang W, Li F,
Liu D, Wu K, Zhu D, Liu S, Shen C, et al: Overexpressed PKMYT1
promotes tumor progression and associates with poor survival in
esophageal squamous cell carcinoma. Cancer Manag Res. 11:7813–7824.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ghelli Luserna di Rorà A, Cerchione C,
Martinelli G and Simonetti G: A WEE1 family business: Regulation of
mitosis, cancer progression, and therapeutic target. J Hematol
Oncol. 13:1262020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen P, Zhang Z and Chen X: Overexpression
of PKMYT1 facilitates tumor development and is correlated with poor
prognosis in clear cell renal cell carcinoma. Med Sci Monit.
26:e9267552020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Qi J, Dou Z, Hu J, Lu L, Dai H,
Wang H and Yang W: Systematic expression analysis of WEE family
kinases reveals the importance of PKMYT1 in breast carcinogenesis.
Cell Prolif. 53:e127412020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xuan ZH, Wang HP, Zhang XN, Chen ZX, Zhang
HY and Gu MM: PKMYT1 aggravates the progression of ovarian cancer
by targeting SIRT3. Eur Rev Med Pharmacol Sci. 24:5259–5266.
2020.PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
von Mering C, Huynen M, Jaeggi D, Schmidt
S, Bork P and Snel B: STRING: A database of predicted functional
associations between proteins. Nucleic Acids Res. 31:258–261. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Warde-Farley D, Donaldson SL, Comes O,
Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT,
et al: The GeneMANIA prediction server: Biological network
integration for gene prioritization and predicting gene function.
Nucleic Acids Res. 38:W214–W220. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan X and Su H: YM155 Down-Regulates
Survivin and induces P53 Up-regulated modulator of apoptosis
(PUMA)-dependent in oral squamous cell carcinoma cells. Med Sci
Monit. 23:1963–1972. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Long HP, Liu JQ, Yu YY, Qiao Q and Li G:
PKMYT1 as a potential target to improve the radiosensitivity of
lung adenocarcinoma. Front Genet. 11:3762020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Wang L, Chen S, Peng H, Xiao L, E
Du, Liu Y, Lin D, Wang Y, Xu Y and Yang K: PKMYT1 is associated
with prostate cancer malignancy and may serve as a therapeutic
target. Gene. 744:1446082020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jeong D, Kim H, Kim D, Ban S, Oh S, Ji S,
Kang D, Lee H, Ahn TS, Kim HJ, et al: Protein kinase,
membrane-associated tyrosine/threonine 1 is associated with the
progression of colorectal cancer. Oncol Rep. 39:2829–2836.
2018.PubMed/NCBI
|
|
21
|
Yadav M, Pradhan D and Singh RP:
Integrated analysis and identification of nine-gene signature
associated to oral squamous cell carcinoma pathogenesis. 3 Biotech.
11:2152021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sumita Y, Yamazaki M, Maruyama S, Abé T,
Cheng J, Takagi R and Tanuma JI: Cytoplasmic expression of SOX9 as
a poor prognostic factor for oral squamous cell carcinoma. Oncol
Rep. 40:2487–2496. 2018.PubMed/NCBI
|
|
23
|
Jung HM, Phillips BL, Patel RS, Cohen DM,
Jakymiw A, Kong WW, Cheng JQ and Chan EK: Keratinization-associated
miR-7 and miR-21 regulate tumor suppressor reversion-inducing
cysteine-rich protein with kazal motifs (RECK) in oral cancer. J
Biol Chem. 287:29261–29272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chou SC, Azuma Y, Varia MA and Raleigh JA:
Evidence that involucrin, a marker for differentiation, is oxygen
regulated in human squamous cell carcinomas. Br J Cancer.
90:728–735. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang F, Gong J, Wang G, Chen P, Yang L and
Wang Z: Waltonitone inhibits proliferation of hepatoma cells and
tumorigenesis via FXR-miR-22-CCNA2 signaling pathway. Oncotarget.
7:75165–75175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bendris N, Arsic N, Lemmers B and
Blanchard JM: Cyclin A2, Rho GTPases and EMT. Small GTPases.
3:225–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Monteiro LS, Diniz-Freitas M,
Warnakulasuriya S, Garcia-Caballero T, Forteza-Vila J and Fraga M:
Prognostic significance of Cyclins A2, B1, D1, and E1 and CCND1
numerical aberrations in oral squamous cell carcinomas. Anal Cell
Pathol (Amst). 2018:72535102018.PubMed/NCBI
|
|
29
|
Li X, Ma XL, Tian FJ, Wu F, Zhang J, Zeng
WH, Lin Y and Zhang Y: Downregulation of CCNA2 disturbs trophoblast
migration, proliferation, and apoptosis during the pathogenesis of
recurrent miscarriage. Am J Reprod Immunol. 82:e131442019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ruan JS, Zhou H, Yang L, Wang L, Jiang ZS
and Wang SM: CCNA2 facilitates epithelial-to-mesenchymal transition
via the integrin αvβ3 signaling in NSCLC. Int J Clin Exp Pathol.
10:8324–8333. 2017.PubMed/NCBI
|
|
31
|
Cheung CT, Bendris N, Paul C, Hamieh A,
Anouar Y, Hahne M, Blanchard JM and Lemmers B: Cyclin A2 modulates
EMT via β-catenin and phospholipase C pathways. Carcinogenesis.
36:914–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li J, Ying Y, Xie H, Jin K, Yan H, Wang S,
Xu M, Xu X, Wang X, Yang K, et al: Dual regulatory role of CCNA2 in
modulating CDK6 and MET-mediated cell-cycle pathway and EMT
progression is blocked by miR-381-3p in bladder cancer. FASEB.
33:1374–1388. 2019. View Article : Google Scholar : PubMed/NCBI
|
